# IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER

> **NIH NIH N01** · NORTHWESTERN UNIVERSITY · 2020 · $162,356

## Abstract

The proposed study is a Phase IIb, double-blinded, placebo-controlled trial of a statin to evaluate the impact of statin treatment on disease progression in 80 patients with liver cirrhosis who have a current Model for End-Stage Liver Disease (MELD) ≤ 20 and no evidence of Hepatocellular carcinoma (HCC).  Participants shall be recruited from hepatology clinics at Cedar Sinai Medical Center (CSMC) and Northwestern University (NWU) and shall include patients who are currently waitlisted, or under evaluation, for a liver transplant.

## Key facts

- **NIH application ID:** 10240245
- **Project number:** 261201200035I-P00004-26100012-1
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** SEEMA KHAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $162,356
- **Award type:** —
- **Project period:** 2016-09-15 → 2022-04-13

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10240245

## Citation

> US National Institutes of Health, RePORTER application 10240245, IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER (261201200035I-P00004-26100012-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10240245. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*